Introduction
The transduction of tumor cells with the herpes simplex virus thymidine kinase (HSV1 TK: EC 2.7.1.21) combined with the prodrug ganciclovir (GCV) is a well characterized form of suicide gene therapy first introduced over 25 years ago [1] . This therapy was conceived on the basis that the guanosine analog GCV is not, or only poorly, accepted as substrate by the cellular thymidine kinases, or other nucleoside kinases, that would catalyze the first phosphorylation step in metabolic activation of this prodrug. Therefore GCV would be physiologically inert, unless converted to the tri-phosphorylated form that acts as substrate of DNA polymerases. The expression of HSV1 TK in tumor cells allows site-specific activation of GCV. Activated GCV thus only causes cell death at the tumor site by DNA damage, and has very little effect on the surrounding cells/tissue. So far, many strategies have targeted the treatment of aggressive malignant brain tumors such as glioblastoma multiforme, however, overall they have had only moderate success in clinical trials [1] [2] [3] [4] [5] . Most recently, the HSV1 TK/GCV-based enzyme/prodrug system has been put forward as an efficient strategy for stem cell-based gene therapy [6, 7] .
Different factors are thought to contribute to the limitations of the HSV1 TK/GCV strategy, one being that GCV is not efficiently phosphorylated by HSV1 TK. Following the delivery of HSV1 TK cDNA to tumor cells, GCV is phosphorylated to 5 0 -monophosphate (GCV-MP) by HSV1 TK, and subsequently converted to 5 0 -diphosphate (GCV-DP) and 5 0 -triphosphate (GCV-TP) by cellular kinases [8] . The GCV-TP metabolite has been implicated in the initiation of the apoptosis pathway, though the exact mechanism whereby the cell becomes apoptotic is still unknown. Briefly, GCV-TP is incorporated in the elongating DNA chain resulting in S-phase cell-cycle arrest, and/or GCV-TP competitively inhibits the cellular DNA polymerases, resulting in inhibition of DNA synthesis, and ultimately apoptosis [9] [10] [11] [12] [13] [14] [15] .
Over the years, extensive kinetic analysis has been performed on HSV1 TK with the aim to improve its kinetic properties with nucleoside analogs as substrates, and thus improve its tumor cell killing capacity. As well as GCV, HSV1 TK also recognizes the nucleoside analogs acyclovir (ACV), penciclovir (PCV), and brivudine (BVDU) as substrates, and accepts the natural nucleosides deoxycytidine (dC), deoxyguanosine (dG), deoxyuridine (dU), deoxythymidine (dT) and thymidylate (dTMP) as substrates [16, 17] . Thus, in the tumor cell context, this promiscuity may also influence the GCV cell-killing efficiency due to competition between GCV and the natural substrates of HSV1 TK. As HSV1 TK has a highest affinity (lowest K m ) for dT, it has been proposed that enabling HSV1 TK to preferentially bind and phosphorylate GCV rather than dT, would improve the cytotoxic effect of the HSV1 TK/ GCV enzyme/prodrug combination [18] [19] [20] [21] [22] . On this basis, random mutagenesis and rational protein engineering studies have focused on generating HSV1 TK variants, which would selectively and efficiently phosphorylate GCV [18] [19] [20] [21] [22] . Several HSV1 TK mutants have been shown to have compromised dT activity while still possessing the ability to phosphorylate GCV.
For our study, we focused on structure-guided mutagenesis of equine herpes thymidine kinase (EHV4 TK: EC 2.7.1.21). Previously, Loubiè re et al. compared thymidine kinases expressed by other members of the herpes virus family and found that both murine and human cell-lines transfected with EHV4 TK, which is expressed by the equine herpes virus type-4, resulted in 3-12 times more GCV-induced cytotoxicity compared to HSV1 TKtransfected cells [23] . Based on the EHV4 TK crystal structure and sequence homologies to HSV1 TK, we have generated EHV4 TK mutants also with the aim to either ablate or reduce the affinity of dT binding and ultimately increase the GCV-induced cell killing sensitivity [24] . We found that the EHV4 TK S144H mutant resulted in residual dT activity and following expression in HEK 293 cells imposed increased GCV sensitivity compared to wildtype EHV4 TK.
Materials and methods

Materials
Oligonucleotides were purchased from IBA GmbH (Gö ttingen, Germany). PCR reagents were from PeqLab (Erlangen, Germany) and restriction enzymes from (New England Biolabs, Ipswich, MA). Dulbecco's Modified Eagle Medium (DMEM) was purchased from Sigma-Aldrich (Steinheim, Germany), L-glutamine and fetal calf serum (FCS) were purchased from PAA Laboratories GmbH (Cö lbe, Germany). G-418 solution, FuGene 1 HD Transfection Reagent and Cell Proliferation Reagent WST-1 were purchased from Roche (Mannheim, Germany). Nucleosides, ACV and GCV were purchased from Sigma-Aldrich.
Anti-GFP IgG antibody was a gift from Dr. Dieter Schmitt (MPI for Biophysical Chemistry, Gö ttingen). Anti-a-tubulin mAb was a gift from Prof. Mary Osborn (MPI for Biophysical Chemistry, Gö ttingen). Anti-nuclear poly(ADP-ribose) polymerase (PARP) IgG was purchased from Cell Signaling (Danvers, MA), IgG antibodies conjugated to horseradish-peroxidase were purchased from DiaNova (Hamburg, Germany).
Molecular biology
The plasmids pUT599[HSV1 TK] and pUT699[EHV4 TK] have been described previously [23] . A maltose-binding protein (MBP)-polyhistidine double affinity fusion of EHV4 TK was obtained by cloning into a modified pMAL c2 vector (New England Biolabs, Ipswich, MA) a fragment of two annealed oligos (5 0 -cgc acc atc acc atc acc acc agg tcg gtg gtg gcg gtg gct tgg ttc cgc gtg gct ctc ata tgg aat tcg-3 0 , and 5 0 -gat ccg aat tcc ata tga gag cca cgc gga acc aag cca ccg cca cca ccg acc tgg tgg tga tgg tga tgg tgc gag ct-3 0 ) to generate a linker coding for the amino acid sequence HHHHHHQVGGGGGLVPRGS with an N-terminal SacI site and C-terminal NdeI, EcoRI and BamHI sites. The fragment was ligated into pMAL c2 via SacI and BamHI, generating the pMAL K4 vector. This MBP-His 6 -tag vector allowed purification of soluble protein by metal affinity chromatography and efficient thrombin protease cleavage (LVPR'GS site) of the fusion protein.
Site-specific mutations of EHV4 TK were generated by overlapextension PCR using overlapping oligonucleotide sets: (EHV4 TK 5 0 -gga att cca tat ggc tgc ttg cgt ac-3 0 , and EHV4 TK 3 0 -gga tcc tca gac gcc cat ctc cgc-5 0 ; EHV4 TK A143Y 5 0 -ccg gtc tact ct acc gta tgc ttt cca g-3 0 , and 3 0 -tac ggt aga gta gac cgg gtg gcg-5 0 ; EHV4 TK S144H 5 0 -gtc gcc cat acc gta tgc ttt cca gc-3 0 , and EHV4 TK S144H 3 0 -tac ggt atg ggc gac cgg gtg-3 0 ) [25] . The EHV4 TK 5 0 oligos contained a BamHI site, and the EHV4 TK 3 0 oligos contained an NdeI site for cloning into the modified pMAL c2 vector. HSV1 TK was cloned into a pET14b vector via NdeI and BamHI sites to create an N-terminal His 6 -tag fusion protein. For expression in mammalian cells, EHV4 TK wild-type and the EHV4 TK mutants were sub-cloned from the pMAL c2 vector by PCR to obtain fragments with N-terminal NdeI and C-terminal BamHI sites. Fragments were then ligated into pEGFP-C1 and pEGFP-N1 vectors (Clontech, Saint-Germain-enLaye, France) modified to contain NdeI in the multiple cloning site.
Protein expression and purification
Escherichia coli BL21 C41 (DE3) was used for recombinant protein production. Cells were grown in LB medium to an OD 600 of 0.7-0.9. Protein overexpression was induced with 0.5-1 mM IPTG. Cells were incubated at 25 8C for 7 h (HSV1 TK) or at 18 8C for 24 h (EHV4 TK), and then harvested by centrifugation. Cell pellets were suspended in buffer A (50 mM Hepes, pH 7.2, 500 mM NaCl, 10% (v/ v) glycerol, 1% (v/v) Triton X-100, 5 mM ß-mercaptoethanol, 0.5 mM PMSF), and lysed by sonication. After centrifugation of the homogenate (12,000 Â g, 30 min, 4 8C), the supernatant was incubated overnight with Ni-NTA agarose (Qiagen, Hilden, Germany). The resin with bound His 6 -tagged protein was washed with buffer A containing 10 mM imidazole. The enzyme moieties were released by thrombin-cleavage (0.5 units/ml) of matrixbound fusion protein, size-checked by PAGE, and quantified using the Bio-Rad dye-binding assay.
Enzyme activity measurements
An NADH-dependent enzyme coupled assay [26] performed on a Kontron Uvikon 943 double beam UV/VIS spectrophotometer was used to determine the thymidine kinase activities by recording the decrease of NADH absorption measured at 340 nm, at 25 8C in the assay buffer (100 mM Tris, pH 7.5, 100 mM KCL, 10 mM MgCl 2 , and 1 mM ATP). For k cat and K m determination, the following range of concentrations were used: GCV, 20-500 mM; D-dT, 1-500 mM; ACV, 20-500 mM.
TK-deficiency rescue assay
The E. coli strain KY895 (l À , tdk-1. IN (rrnD-rrnE)1, ilv-276; E. coli genetic stock center nr. 4842) lacks TK activity, but it is able to synthesize thymidine mono-phosphate (TMP) from deoxyuridine monophosphate (dUMP) through the thymidylate synthase (TS) pathway. A block of this pathway by the TS inhibitor 5-fluorodeoxyuridine (5-FdUrd) prevents growth of E. coli KY895. Complementation of the missing TK activity by plasmid-encoded enzymes was tested by transforming this strain with E. coli TK, HSV1 TK, EHV4 TK, or EHV4 TK A143Y cloned into pGEX RB and replating transformants onto selection agar (2% peptone, 0.5% NaCl, 0.2% glucose, 2 mg/ml Thd, 12.5 mg/ml Urd, 100 mg/ml ampicillin, 10 mg/ml 5-FdUrd).
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) measurements were performed in an OMEGA titration calorimeter (Microcal). The reference cell was filled with water. All solutions were degassed prior to experiments. Protein samples were dialyzed over night against buffer A, concentrated to 20-25 mM using Vivaspin concentrators (Sartorius, Gö ttingen, Germany), and loaded into the calorimeter cell (1.45 ml volume). Thymidine was dissolved in the dialysis buffer at a concentration 25-fold higher than that of EHV4 TK or EHV4 TK A143Y. The thymidine solution was titrated in 8 ml aliquots (12 injections, 3 min intervals between injections) EHV4 TK or EHV4 TK A143Y. Raw data were integrated with the Origin 1 software supplied with the instrument.
Cell-culture and stable cell-line generation
The HEK 293 cell-line was cultured in standard complete DMEM medium, which is DMEM supplemented with 10% heatinactivated FCS and L-glutamine and maintained at 37 8C in humidified atmosphere containing 5% CO 2 .
To generate HEK 293 stable cell-lines, cells were seeded into 10 cm dishes and transfected using FuGene 1 HD Transfection Reagent according to the manufacturer's instructions. The standard complete DMEM medium was exchanged to complete DMEM supplemented with 900 mg/ml G-418. After 7-10 days, colonies were observed, isolated using a pipette tip under an inverted light-microscope, and transferred to 12-well plates. After 2-3 days, the stable colonies were monitored using a fluorescencemicroscope and further sub-cultured. The established stable celllines were maintained in complete DMEM medium containing 300 mg/ml G-418.
Cell proliferation/survival
For GCV dose-response analysis, HEK-stable cell-lines were seeded in 96 well plates. GCV in the range of 1 nM-100 mM was added, with triplicate wells for each concentration. After 96 h, WST-1 proliferation assays were performed according to the manufacturer's instructions and analyzed on a mQuant microplate spectrophotometer (Bio-Tek Instruments) at 450 nm.
The assay results at different concentrations of GCV were compared to the wells without GCV (control) and the percentage cell survival plotted. The GCV EC 50 values were calculated with GraphPad Prism 5 software (Nonlinear regression fitting; standard slope (Hill-slope = 1.0)).
Western-blot analysis
The stable HEK293 cell-lines cultured in 6-well plates were lysed with standard lysis-buffer (10 mM K 2 HPO 4 , 150 mM NaCl (pH 7.4), 5 mM EDTA, 5 mM EGTA, 0.5 mM PMSF, and protease inhibitor cocktail). Cell lysates were snap-frozen in liquid nitrogen, thawed, subjected to 10 strokes through a 20-gauge needle and centrifuged for 10 min at 13,000 rpm, 4 8C. The total protein concentration of supernatants was measured by Bradford assay. Samples of the cell-lysate supernatants were prepared in 6Â Laemmli buffer, heated for 5 min at 95 8C. The supernatant samples were subjected to SDS-PAGE in 12.5% acrylamide gels (15-20 mg total protein per lane), and transferred to nitrocellulose.
Nitrocellulose membranes were incubated with Ponceau S stain to assess transfer and loading, and then blocked with 5% skimmed milk for 1 h at room temperature. The membranes were incubated with anti-GFP IgG antibody in 1% milk for 2-3 h at room temperature, washed and incubated with horseradish peroxidase-conjugated anti-rabbit IgG in 1% milk for 1 h at room temperature. The membranes were re-probed with anti-a-tubulin mAb to show loading of lanes. Quantitative analysis of Westernblot data was performed using Image J 1.44p software (http:// rsbweb.nih.gov/ij/).
For the analysis of poly(ADP-ribose) polymerase (PARP) cleavage, the supernatant samples were subjected to SDS-PAGE in 10% acrylamide gels, blotted, membranes stained with Ponceau S incubated with anti-PARP IgG overnight at 4 8C. Anti-PARP IgG detects both full length PARP (116 kDa) and the large caspasecleaved fragment of PARP (89 kDa).
Confocal microscopy
Cells were grown on 20 mm glass cover-slips, fixed with 4% paraformaldehyde for 10 min at room temperature, incubated with DAPI (300 nM) for 2 min at room temperature, and the coverslips were mounted in Mowiol. The images were taken with 25x objective on a Zeiss LSM5 confocal microscope.
Results
Kinetic analysis comparison of wild-type HSV1 TK, wild-type EHV4 TK, and EHV4 TK mutants
In the case of HSV1 TK, Balzarini et al. have generated HSV1 TK mutants with the aim of ablating dT kinase activity, yet preserving purine nucleoside analog activity [22] . Through a structural modeling approach, they found individual amino acid mutations, where alanine residues substituted to phenylalanine or histidine at positions 167 or 168 (A167F or A168H, respectively) successfully compromised dT activity, but preserved GCV activity. As the tertiary structures of HSV1 TK and EHV4 TK overlap, and they share many similarities in secondary structure, we proposed that mutations at the corresponding sites in EHV4 TK would have similar effects [24] . As shown in the amino acid alignment of HSV1 TK and EHV4 TK, positions 167 and 168 in HSV1 TK correspond with positions 143 and 144 in EHV4 TK (Fig. 1A) . We constructed two different mutations, A143Y and S144H, also with the aim to hinder dT activity, yet preserve GCV activity. As the crystal structure of EHV4 TK bound to its natural substrate thymidine (dT) has been solved [24] , we used this structural information to create diagrams, which reveal the structural positions of both the A143Y and S144H mutations (Fig. 1B and C) . In order to visualize the dT binding site more clearly, alpha-helices 1 and 12 (a1 and a12) and beta-sheet 5 (b5) were removed. In the case of the A143Y mutation, the steric clash of the larger aromatic side chain of tyrosine with the dT ring can clearly be seen (Fig. 1B) . The S144H mutation is presumed to affect dT binding through a steric hindrance created by the histidine ring (Fig. 1C) .
The steady-state kinetics of each mutant, EHV4 TK A143Y and EH4TK S144H was analyzed and compared to wild-type EHV4 TK and HSV1 TK ( Table 1 ). The K m values and turn-over rates were measured for dT and GCV. As previously reported, dT is the preferred substrate for both HSV1 TK WT and EHV4 TK WT (K m = 12 mM, and 5.8 mM, respectively). Of the two EHV4 TK mutants, the EHV4 TK S144H mutation resulted in a much higher K m (>500 mM), and the EHV4 TK A143Y mutation resulted in the total loss of dT activity. To observe whether a low residual dT activity for EHV4 TK A143Y existed which was not detected by the steady-state kinetic measurements, a complementation assay for TK activity in E. coli was performed, and indeed revealed that EHV4 TK A143Y lost the capacity to genetically complement the thymidine kinase-deficient mutant strain (Fig. 2(A) and (B) ). In this assay, 5-FdUrd is included in the selection media, and under these conditions, the generation of TMP becomes dependent on an active thymidine kinase enzyme. Here, E. coli TK, HSV1 TK, and EHV4 TK were able to rescue the TK-deficiency of the E. coli KY895 strain; however, EHV4 TK A143Y did not (Fig. 2(A) and (B) ). This indicates that the mutant EHV4 TK A143Y enzyme has lost the capacity to phosphorylate the natural substrate thymidine.
Furthermore, we performed isothermal titration calorimetry (ITC) to analyze if the EHV4 TK A143Y mutant enzyme had lost the ability to bind dT (Fig. 2(C) and (D) ). The binding of dT to EHV4 TK WT was found to be exothermic, the downward peaks indicating heat liberation on injection of the ligand solution into the protein solution. In the case of EHV4 TK A143Y, a trace was observed that resulted solely from the ligand dilution, indicating that the mutant protein could no longer interact with dT.
Although EHV4 TK S144H did not lose dT phosphorylation activity, the K m for dT increased over 100-fold (K m > 500 mM). 
Generation of stable EHV4 TK, EHV4 TK A143Y, and EHV4 TK S144H expressing HEK 293 cell-lines
Based on our steady-state kinetic results for the EHV4 TK mutants, we aimed to study whether the cell-killing ability of the EHV4 TK A143Y or EHV4 TK S144H mutants with the prodrug GCV is indeed superior to wild-type EHV4 TK. To do this, we generated several stable cell-lines. In order to observe the intracellular location of EHV4 TK WT and the EHV4 TK mutants, we constructed N-terminal GFP fusions of each. Following the transient transfection of HEK 293 cells with GFP-EHV4 TK WT, unusual polymeric structures were seen (data not shown). We attributed this observation to the fact that EHV4 TK is predicted to form a slipknot during folding which involves the N-terminal part of the enzyme [27] , and the addition of N-terminal GFP somehow interfered with this folding. Therefore, we created C-terminal GFP fusions instead. In this case, uniform cytosolic and nuclear distribution of EHV4 TK WT-GFP, EHV4 TK A143Y-GFP and EHV4 TK S144H-GFP were visualized in HEK 293 cells by confocal microscopy (Fig. 3A) , and stable HEK 293 cell-lines expressing each were generated.
The morphology of each stable cell-line and the mother HEK 293 cell-line were similar (data not shown). As both the EHV4 TK A143Y and EHV4 TK S144H mutants have either lost dT activity, or have greatly reduced dT activity compared to EHV4 TK WT, we compared proliferation rates of each stable cell-line and found that they were similar over a period of 48 h (Fig. 3B ).
Sensitivity of EHV4 TK WT-GFP, EHV4 TK A143Y-GFP, and EHV4 TK S144H-GFP stable cell-lines to GCV
Western blot analysis of whole-cell lysates from each stable cell-line revealed the EHV4 TK protein expression levels were not equal (Fig. 4A) . The relative EHV4 TK expression compared to Table 1 Kinetic parameters of wild-type HSV1 TK, wild-type EHV4 TK and EHV4 TK mutants. NADH-dependent enzyme-coupled activity measurements were performed at 37 8C in the assay buffer (100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl 2 , and 1 mM ATP). For k cat and K m determination, the following ranges of concentrations were used (GCV, 20-500 mM; D-dT, 1-500 mM; ACV, 20-500 mM) (n = 2-5, AESD). n.d. Indicates not determined due to very high K m . The standard deviations for the k cat /K m ratios were calculated by Propagation of Error.
Thy GCV a-tubulin indicated that the EHV4 TK WT-GFP stable cell-line expressed around 2-fold more EHV4 TK than did the EHV4 TK S144H-GFP stable cell-line, and 6-fold more EHV4 TK than did the EHV4 TK A143Y-GFP stable cell-line. The sensitivity of the stable cell-lines to GCV was measured by performing dose-response curves (Fig. 4(D) and (F) ) and calculating the EC 50 values following 96 h of GCV incubation (Fig. 4B) . The EC 50 values obtained show that the GCV EC 50 value of EHV4 TK S144H (0.1 AE 0.02 mM) is lower than that of EHV4 TK WT (0.6 AE 0.2 mM), despite the fact that EHV4 TK WT is more highly expressed. In the case of the EHV4 TK A143Y-GFP stable cell-line, which has the lowest EHV4 TK expression, the EC 50 value was measured at 1.8 AE 0.5 mM. As an additional control, HEK 293 cells were transiently transfected with pEGFP-N1 vector only (mock) and EHV4 TK WT-GFP, and subjected to 72 h of GCV-treatment (1 mM and 10 mM) (Fig. 4C) . No cytotoxic effect of GCV was observed on the cells expressing GFP only (mock).
We also tested the sensitivity of our stable cell-lines to the nucleoside analog prodrug ACV (Fig. 5) . It can be seen that in all cases a high concentration (500 mM) is required to achieve over 90% cell death after 72 h.
Time courses of EHV4 TK WT-GFP and EHV4 TK S144H-GFP stable cell-line survival and induction of PARP cleavage following GCV incubation
Comparing expression levels and EC 50 values of EHV4 TK WT-GFP, EHV4 TK A143Y-GFP and EHV4 TK S144-GFP stable cell-lines (Fig. 4(A) and (B) ), we followed cell-survival and PARP cleavage over a time course for the two most GCV sensitive stable cell-lines. Time-courses of the survival of the EHV4 TK WT-GFP and EHV4 TK S144-GFP stable cell-lines following incubation over a range of GCV concentrations (0.5 mM, 1 mM, 10 mM) were performed. At 0.5 mM GCV, significant cytotoxicity was only observed with the EHV4 TK S144H-GFP stable cell-line (GCV EC 50 = 0.1 mM), at 24 h onwards resulting in 25% cell survival at 96 h (Fig. 6A) . Some cell death also occurred at 0.5 mM GCV with the EHV4 TK WT-GFP stable cell-line (GCV EC 50 = 0.6 mM), with 70% cell survival at 96 h. At 1 mM GCV, a sharper decline in cell survival was seen with EHV4 TK S144H-GFP as compared to EHV4 TK WT-GFP, with, at 96 h, 15%
and 50% of cells surviving, respectively (Fig. 6B) . Finally, at 10 mM GCV concentration, which is far in excess of the GCV EC 50 s for both EHV4 TK WT-GFP and EHV4 TK S144H-GFP stable cell-lines, the sharpest increase in cell death was observed, and the time-profile of cell death was similar for both cases (Fig. 6C) . At 48 h, only 50-60% of cells survived, and at 96 h only 1-10% of cells survived.
Time courses were also performed to detect the cleavage of PARP (nuclear poly(ADP-ribose) polymerase), an indicator of down-stream caspase activation and thus apoptosis (Fig. 6D) . In both the EHV4 TK WT-GFP and EHV4 TK-S144H stable cell-lines, following 0.5 mM GCV incubation, the most PARP cleavage was observed at the 40 h time-point.
Discussion
In the quest to improve the efficacy of the HSV1 TK/GCV-based enzyme/prodrug gene therapy approach, where immunosuppressive concentrations of GCV are needed to give the required response, many different factors have to be considered. One focal point has been to improve the efficiency of the HSV1 TK gene delivery system itself. Previously, adenovirus vectors and retroviral vectors have been used in different stages of clinical trials to treat glioblastomas, without significant success [3, 4, 28] . This lack of success is attributed to the poor transduction of the HSV1 TK gene to the tumor, and the fact that transduction lacks target specificity. Recent approaches, which aim to improve transduction efficiency, to specifically target the tumor, and also to reduce immunogenicity include recombinant non-viral vectors, mesenchymal stem cells, and the use of Bifidobacterium as gene delivery vehicle [29] [30] [31] . Furthermore, extensive structural and kinetic studies of HSV1 TK have focused on improving the catalytic activity of HSV1 TK for ACV and GCV as substrates [18] [19] [20] [21] [22] . Our study aimed to modify the catalytic activity of another member or the herpes thymidine kinase family, the equine herpes virus-4 thymidine kinase (EHV4 TK). Previous research found that a human osteosarcoma cell-line expressing EHV4 TK was rendered 12-fold more sensitive to GCV compared to the same cell-line expressing HSV1 TK [23] . Therefore, in line with the studies focusing on HSV1 TK protein engineering, we investigated if it is possible to further improve EHV4 TK/GCV cytotoxicity by designed enzyme variants.
Firstly, we performed structure-based site-directed mutagenesis to enable EHV4 TK selectively to accept GCV as a substrate over the natural nucleoside dT. Residues A167 and A168 appeared to be important in the discrimination of GCV and dT binding to HSV1 TK [18, 22] . Following sequence and structural comparisons of HSV1 TK and EHV4 TK [24] , we proposed that the homologous mutations A143Y and S144H would confer a shift from pyrimidine activity to predominantly purine activity. This was indeed the case: The EHV4 TK A143Y variant lost the ability to bind dT, and although the EHV4TK S144H mutant still had residual dT activity, its K m increased more than 100-fold. The high phosphorylation rate of GCV by wild-type EHV4 TK was maintained following the A143Y mutation, and was even increased 3-fold with the S144H mutation. Although both mutations resulted in increased K m values for GCV, it can be assumed that in a cellular context, the substrate competition between dT and GCV would be ruled out, resulting in an increase in the GCV phosphorylating activity, and thus increase the GCV-MP pool available to participate in the next step of the phosphorylation pathway. Importantly, the presence of the thymidine kinase-deficient enzyme variant does not perturb nucleotide levels, and will not affect cells in the absence of GCV.
We tested this hypothesis by generating mammalian cell-lines expressing EHV4 TK variants and wild-type EHV4 TK. For ease of handling, we chose the HEK 293 cell-line to generate stable cell-lines and a GFP fusion system for visualization. Initially, we encountered a curious hurdle, whereby our N-terminal GFP EHV4 TK wild-type construct when transiently transfected into HEK 293 cells resulted in the formation of 'polymeric structures'. As EHV4 TK does not possess a cellular localization signal sequence, we had expected to observe GFP-EHV4 TK uniformly distributed throughout the cytosol and nucleus. As this was not the case, we believe that, due to the N-terminal GFP fusion moiety, misfolding may occur as EHV4 TK is one of few proteins reported to form a slipknot during folding [27] . As the slipknot is proposed to be formed by the passing of the EHV4 TK N-terminal region into a structural opening, we constructed a C-terminal GFP fusion of EHV4 TK with the assumption that misfolding would in this case not occur. Indeed, upon transfection of HEK 293 cells with EHV4 TK WT-GFP, EHV4 TK A143Y-GFP or EHV4 TK S144H-GFP, a uniform cytosolic and nuclear expression was observed. Furthermore, the stable cell-lines created with these constructs displayed similar morphology and proliferation rates (Fig. 3) .
Although Western blot analysis of EHV4 TK WT-GFP, EHV4 TK A143Y-GFP, and EHV4 TK S144H-GFP protein expression showed different levels, we tested their sensitivity to GCV. The viability of the stable cell-lines after 96 h following exposure to differing concentrations of GCV was measured by WST-1 assays, and dose-response curves were generated. Surprisingly, considering the protein expression levels, the EC 50 values (Fig. 4B) derived from the dose-response curves indicated that the EHV4 TK S144H-GFP stable cell-line was more sensitive to GCV than that of the more highly expressing EHV4 TK WT-GFP stable cell-line.
The EC 50 value of EHV4 TK S144H-GFP (0.1 AE 0.02 mM) is lower than that of EHV4 TK WT-GFP (0.6 AE 0.2 mM), despite the fact that EHV4 TK WT-GFP is more highly expressed. In the case of the EHV4 TK A143Y-GFP stable cell-line, which showed the lowest EHV4 TK expression level, the EC 50 value was measured at 1.8 AE 0.5 mM. Exposing each of the EHV4 TK stable cell-lines to the nucleoside analog prodrug ACV for 72 h, resulted in significant cell death only at high concentrations (500 mM) (Fig. 5) . Previous studies have shown that not only does ACV have a different mechanism of cellular cytotoxicity compared to GCV, the ACV-TP metabolite has also very short intra-cellular half-life compared to GCV-TP [32, 33] . Therefore, we expected that our EHV4 TK mutants would not confer increased ACV sensitivity compared to EHV4 TK WT. Taken together, these results indicate that HEK 293 cells expressing the EHV4 TK S144H-GFP mutant are more sensitive to GCV compared to HEK 293 cells expressing EHV4 TK WT-GFP or EHV4 TK A143Y-GFP, whereas sensitivity to ACV remains unchanged. It remains to be analyzed whether the higher EC 50 value observed for EHV4 TK A143Y-GFP could be related its lower intracellular expression level.
Once GCV is phosphorylated by a viral thymidine kinase, in our case EHV4 TK, it is further phosphorylated by cellular kinases resulting in diphosphate (GCV-DP) and triphosphate (GCV-TP) forms [8] . Previously, it has been reported that GCV-TP is incorporated into cellular DNA, cells complete one round of mitosis, arrest in S-phase of the cell-cycle resulting in doublestranded breaks, and ultimately go into apoptosis [15, 34] . The appearance of apoptotic cells at 24 h, which increased greatly at 36-72 h has been reported following the incubation of a CHO cellline stably expressing HSV1-TK with GCV [15] . Our findings are in line with this apoptotic time-scale, as we observed in the case of both EHV4 TK WT-GFP and EHV4 TK S144H-GFP that at GCV concentrations in excess of the EC 50 value, cell-death occurs from 24 h onwards (Fig. 6(A) and (C) ). Furthermore, analysis of the cleavage of nuclear poly(ADP-ribose) polymerase (PARP) revealed that most cleavage occurred at the 40 h time-point (Fig. 6D) .
Overall, our results indicate that the EHV4 TK S144H-GFP mutant, which preferentially phosphorylates the purine nucleoside analog GCV rather than dT, confers HEK 293 cells with increased sensitivity to GCV compared to EHV4 TK WT-GFP. Our thymidine kinase-deficient enzyme variant could be of particular interest for use in recently developed GCV-dependent suicide gene therapy systems that are based on controllable promoters that appear to be highly effective in certain tumors [35, 36] .
Funding
Supported by the Deutsche Forschungsgemeinschaft and the Max-Planck-Gesellschaft (T.M. and M.K.).
